VRAX has 36-month beta value of 0.90. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VRAX is 1.73M, and currently, short sellers hold a 0.69% ratio of that float. The average trading volume of VRAX on May 08, 2024 was 35.29K shares.
VRAX) stock’s latest price update
Virax Biolabs Group Ltd (NASDAQ: VRAX) has experienced a rise in its stock price by 16.37 compared to its previous closing price of 0.63. However, the company has seen a gain of 15.87% in its stock price over the last five trading days. PennyStocks reported 2023-12-27 that Penny stocks, defined as stocks that trade for less than $5 per share, can be appealing to investors due to their low prices and potential for large percentage gains. However, penny stocks also carry more risk than regular stocks.
VRAX’s Market Performance
VRAX’s stock has risen by 15.87% in the past week, with a monthly drop of -8.75% and a quarterly drop of -9.43%. The volatility ratio for the week is 12.94% while the volatility levels for the last 30 days are 11.93% for Virax Biolabs Group Ltd The simple moving average for the past 20 days is 7.22% for VRAX’s stock, with a -64.13% simple moving average for the past 200 days.
VRAX Trading at -6.90% from the 50-Day Moving Average
After a stumble in the market that brought VRAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.59% of loss for the given period.
Volatility was left at 11.93%, however, over the last 30 days, the volatility rate increased by 12.94%, as shares sank -5.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.98% lower at present.
During the last 5 trading sessions, VRAX rose by +15.87%, which changed the moving average for the period of 200-days by -81.89% in comparison to the 20-day moving average, which settled at $0.6788. In addition, Virax Biolabs Group Ltd saw -50.00% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for VRAX
Current profitability levels for the company are sitting at:
- -88.25 for the present operating margin
- 0.11 for the gross margin
The net margin for Virax Biolabs Group Ltd stands at -87.31. The total capital return value is set at -1.12. Equity return is now at value -129.10, with -112.36 for asset returns.
Based on Virax Biolabs Group Ltd (VRAX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -29.39. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -438.11.
Currently, EBITDA for the company is -5.73 million with net debt to EBITDA at 0.71. When we switch over and look at the enterprise to sales, we see a ratio of -40.38. The receivables turnover for the company is 0.43for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.59.
Conclusion
To put it simply, Virax Biolabs Group Ltd (VRAX) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
